Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?

Simply Wall St.07-29

HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655887547?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-29 02:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655887547","market":"nz","top_or_hot":-1,"title":"Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?","media":"Simply Wall St.","content":"<div>\n<p>HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-29 02:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MUYY","symbol_name":"GraniteShares YieldBOOSTMU ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog","article_id":"2655887547","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2655887547","pubTimestamp":1785262928,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and development of biologic drugs.\nSee our latest analysis for HBM Holdings.\nAgainst this backdrop, HBM Holdings has been volatile, with the share price falling 1.74% over the past day but posting a 23.26% 1 month share price return. The 3 year total shareholder return is very large, signalling strong...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"MUYY":"GraniteShares YieldBOOSTMU ETF","02142":"和铂医药-B","DISK":"Tema Memory ETF","MUD":"1倍做空MU ETF-Direxion","MUZ":"2倍做空MU ETF-Defiance","BK1574":"生物医药B类股","MULL":"2倍做多MU ETF-GraniteShares","BK1583":"高瓴概念","MIC":"2倍做多MU ETF-Corgi","HBM":"HudBay Minerals Inc","BK4588":"碎股","DRMP":"Tuttle Capital Memory Stack Income Blast ETF","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","DRMY":"XFUNDS Memory Income ETF","COPP":"Sprott Copper Miners ETF","HBMX":"Tuttle Capital Concentrated Memory Stack ETF","DRAL":"2倍做多DRAM ETF-Defiance","RAM":"2倍做多DRAM ETF-T-REX","DRAM":"Roundhill Memory ETF","MUU":"2倍做多MU ETF-Direxion","BK4168":"多种金属与采矿","BK1161":"生物科技"},"translate_title":"随着国药生物药财团的形成，HBM Holdings (SEHK:2142) 的估值是否被低估？","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/a3f17876d30e588a0cd1a495dcc1f5ba","symbols_score_info":{"MUU":0.6,"DRMY":1.5,"DRMP":1.5,"DRAL":0.6,"MUD":0.6,"RAM":0.6,"MUZ":0.6,"DRAM":1.5,"MIC":0.6,"HBM":0.9,"MULL":1.5,"DCF":1,"HBMX":1.5,"MUYY":0.6,"02142":0.9,"DISK":1.5,"COPP":0.6},"content_text":"HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and development of biologic drugs. See our latest analysis for HBM Holdings. Against this backdrop, HBM Holdings has been volatile, with the share price falling 1.74% over the past day but posting a 23.26% 1 month share price return. The 3 year total shareholder return is very large, signalling strong longer term momentum despite some recent setbacks. If this kind of biotech news has your attention, it could be a good moment to see what else is moving in healthcare by checking out 127 healthcare AI stocks After HBM Holdings' sharp 1 month rebound and the wide gap between the current HK$12.40 price and analyst and intrinsic value estimates, the next step is to identify where fair value most plausibly sits. AdvertisementPrice-to-Earnings of 15x: Is it justified? On pure earnings terms, HBM Holdings trades on a P/E of 15x, which sits well below several key comparison points in the biotech space. The P/E multiple compares the current share price with the company’s earnings per share. For a biopharmaceutical business like HBM Holdings, it reflects how the market values the current earnings stream from its antibody platform and pipeline projects. HBM Holdings is described as good value on P/E when lined up against both the Asian biotech industry average of 31.4x and a peer average of 46.2x. That is a wide gap. However, the estimated fair P/E for the stock is 10.3x, which implies the current 15x multiple sits above the level that regression based modelling suggests the market could move towards over time. Explore the SWS fair ratio for HBM Holdings Result: Price-to-Earnings of 15x (ABOUT RIGHT) However, HBM Holdings still faces risks, including pressure on revenue and net income growth, and the possibility that intrinsic value estimates will continue to lag the current share price. Find out about the key risks to this HBM Holdings narrative. Another view on HBM Holdings using cash flows The P/E comparison paints HBM Holdings as cheaper than many biotech peers, yet the SWS DCF model points in a different direction. At HK$12.40, the stock trades above an estimated cash flow value of HK$9.22, which implies a premium to the model’s view of fair value. That raises a practical question for investors: Which signal deserves more weight, the earnings multiple or the cash flow math? Look into how the SWS DCF model arrives at its fair value. 2142 Discounted Cash Flow as at Jul 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out HBM Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 246 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps With mixed signals around HBM Holdings, it makes sense to move fast and review the full picture for yourself instead of relying on headlines alone. To weigh the upside potential against the concerns in a balanced way, start by checking the 2 key rewards and 2 important warning signs Looking for more investment ideas beyond HBM Holdings? If HBM Holdings has sharpened your focus on opportunities, do not stop here. Use the tools available now so you do not miss other compelling setups.  Target potential mispricings by reviewing 246 high quality undervalued stocks that pair solid fundamentals with room for a better entry point. Focus on resilience by scanning 302 resilient stocks with low risk scores that score well on balance sheet strength and risk metrics. Get ahead of the crowd by checking the screener containing 513 high quality undiscovered gems that combine quality traits with relatively low market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if HBM Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655887547","isCrawlerRequest":true}